Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Abeona Therapeutics Inc.

News headline image
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Date of First Quarter Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.